Gilead Sciences, Inc. (GILD) says its experimental drug Remdesivir showed clinical improvement in 68% of Covid-19 patients, who were administered the drug on a compassionate-use basis. The details were published in The New England Journal of Medicine.
from RTT - Before the Bell https://ift.tt/2xtf2cr
via IFTTT
No comments:
Post a Comment